Ieq Capital LLC Has $870,000 Stock Position in Insulet Corporation $PODD

Key Points

• Ieq Capital LLC significantly increased its position in Insulet Corporation by 304.4%, acquiring a total of 3,312 shares valued at approximately $870,000.
• Insulet reported earnings of $1.17 per share for the latest quarter, exceeding estimates and marking a 32.9% increase in revenue year-over-year.
• Analysts have a consensus rating of "Moderate Buy" for Insulet with an average target price of $332.71, indicating strong support for the stock's performance.

Ieq Capital LLC raised its holdings in shares of Insulet Corporation (NASDAQ:PODD - Free Report) by 304.4% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,312 shares of the medical instruments supplier's stock after acquiring an additional 2,493 shares during the period. Ieq Capital LLC's holdings in Insulet were worth $870,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. GAMMA Investing LLC grew its holdings in shares of Insulet by 27,298.6% during the first quarter. GAMMA Investing LLC now owns 664,141 shares of the medical instruments supplier's stock valued at $1,744,100,000 after buying an additional 661,717 shares in the last quarter. American Century Companies Inc. boosted its stake in shares of Insulet by 34.8% during the 1st quarter. American Century Companies Inc. now owns 1,152,606 shares of the medical instruments supplier's stock worth $302,686,000 after acquiring an additional 297,734 shares in the last quarter. Nuveen LLC acquired a new position in shares of Insulet during the 1st quarter worth about $74,163,000. Kayne Anderson Rudnick Investment Management LLC lifted its position in shares of Insulet by 1,316.5% during the 1st quarter. Kayne Anderson Rudnick Investment Management LLC now owns 193,511 shares of the medical instruments supplier's stock worth $50,818,000 after purchasing an additional 179,850 shares during the last quarter. Finally, Vanguard Group Inc. lifted its position in shares of Insulet by 2.1% during the 1st quarter. Vanguard Group Inc. now owns 8,668,952 shares of the medical instruments supplier's stock worth $2,276,553,000 after purchasing an additional 178,976 shares during the last quarter.

Analyst Ratings Changes

Several equities analysts recently weighed in on the company. Canaccord Genuity Group boosted their price objective on Insulet from $331.00 to $353.00 and gave the stock a "buy" rating in a research report on Friday, August 8th. Citigroup reaffirmed a "buy" rating on shares of Insulet in a report on Tuesday, July 8th. Truist Financial began coverage on Insulet in a report on Monday, June 16th. They issued a "buy" rating and a $365.00 price target for the company. Wolfe Research raised Insulet from a "peer perform" rating to an "outperform" rating and set a $350.00 price target for the company in a report on Tuesday, May 13th. Finally, Wall Street Zen raised Insulet from a "hold" rating to a "buy" rating in a report on Saturday, August 9th. Sixteen analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $332.71.

Insulet Price Performance

NASDAQ PODD traded up $1.96 during trading hours on Friday, reaching $348.43. 498,473 shares of the company's stock were exchanged, compared to its average volume of 584,368. The stock has a market cap of $24.53 billion, a PE ratio of 105.91, a price-to-earnings-growth ratio of 2.92 and a beta of 1.36. Insulet Corporation has a one year low of $211.27 and a one year high of $350.00. The firm has a fifty day moving average of $307.55 and a 200-day moving average of $289.86. The company has a current ratio of 2.26, a quick ratio of 1.81 and a debt-to-equity ratio of 0.64.

Insulet (NASDAQ:PODD - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $1.17 EPS for the quarter, beating analysts' consensus estimates of $0.92 by $0.25. The firm had revenue of $649.10 million for the quarter, compared to analyst estimates of $612.31 million. Insulet had a return on equity of 23.78% and a net margin of 10.01%.The business's quarterly revenue was up 32.9% compared to the same quarter last year. During the same period last year, the company earned $0.55 EPS. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. On average, equities research analysts predict that Insulet Corporation will post 3.92 earnings per share for the current fiscal year.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.